Biomerieux Norge
Sells in-vitro diagnostic instruments and tests to hospital, clinical and food-safety labs in Norway
About Biomerieux Norge
Biomerieux Norge AS is registered in Norway as part of the bioMérieux group, which develops in-vitro diagnostic systems and assays. The group's portfolio includes VITEK MS PRIME, VIDAS KUBE, BIOFIRE FILMARRAY TORCH, BIOFIRE SPOTFIRE, SPINCHIP hs-cTnI, GENE-UP TYPER and ENDONEXT endotoxin assays. Application areas include sepsis, antimicrobial stewardship, respiratory infections, point-of-care testing, food safety and pharmaceutical quality control.
Customers include hospital and clinical laboratories, healthcare professionals, and food and pharmaceutical manufacturers. Revenue comes from product sales and customer service for these products.
The bioMérieux group has worked in in-vitro diagnostics since 1963 and describes itself as a family-led, independent company. Its teams are located in 45 countries and serve 160 countries through a distribution network, with nearly 2,000 scientists worldwide. The Norwegian entity was founded in 1999 and has its headquarters in Oslo.
Product: In-vitro diagnostic instruments and assays for microbiology, immunoassay, molecular testing, point-of-care and food and pharma quality control.
Public tenders won
8 tenders won since 1 Jan 2024 from 7 public buyers in Finland, Norway, worth €3.8M as awarded. From EU award notices (TED) that name Biomerieux Norge by its registry number.
- 4 May 2026 HUS-yhtymä · Mikrobiologian nukleiinihappojen eristyslaitteisto · €166k notice
- 3 Mar 2026 Nordlab hyvinvointiyhtymä · Multiplex-NhO reagenssien hankinta bakteeripneumonia- ja niveltulehdusdiagnostiikkaan · €480k notice
- 3 Dec 2025 Folkehelseinstituttet · 25/01335 Framework agreement for antibiotic products for resistance provision - The Norwegian Institute of Public Health notice
- 25 Nov 2025 Varsinais-Suomen hyvinvointialue · KTE102/25 Pipetointiautomaatti virusten ja bakteerien nukleiinihappojen eristykseen sekä laitesidonnaiset reagenssit · €344k notice
- 27 May 2025 ISLAB hyvinvointiyhtymä · Huoltosopimus ISLABin omistamille PreviColor, Filmarray ja Vitek MS Prime -laitteille · €376k notice
- 2 Oct 2024 NordLab hyvinvointiyhtymä · Maldi-Tof analysaattorien hankinta · €56k notice
Jobs at Biomerieux Norge
More health & medtech companies
BLID
Dental clinics providing examinations, hygiene and other dental treatments to patients in OsloNew on EvolcBlikk Øyeklinikk
Eye specialist clinic providing ophthalmology consultations and treatment for patients in OsloNew on EvolcBlindheim Tannlegesenter
Dental clinic in Ålesund providing general dentistry, oral surgery and oral medicine to patientsNew on EvolcBo I Hop
A private shared-living home in Gaupen for older adults seeking meals, housekeeping and communityYoung companyNew on EvolcBo Og Bistand
Care and support services in Finnsnes, NorwayBogerud Legesenter
General practitioner clinic in Oslo offering appointments, prescription renewals and administrative contact for patientsNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Analytics
- Adobe Experience Platform TagsHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Content delivery
- FastlyHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerx-served-by
- Response headerx-served-by
- Response headerx-served-by
Content management
- Adobe Experience ManagerHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Forms
- Google reCAPTCHAHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Privacy & consent
- OneTrustHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.